Investor Presentation


Frankfurt, 20 November 2018

Constantijn van Rietschoten, CCO



Contents

1.	Personalized Medicine	3
2.	Pharmaceutical Art	7
3.	Fagron	14
4.	Fagron Innovations	26
5.	H1-2018 Results	32
6.	Q3-2018 Trading Update	47
7.	Shareholder Structure	54



FAGRON

Tailoring of a treatment to the personal characteristics of a person, based on the genes, proteins and lifestyle



Genetic test to reveal predisposition to diseases



Prevention of diseases



Early detection of diseases



Accurate diagnosis




Personalized treatment

Global Market for Personalized Medicine




Global Market for Personalized Medicine



Process from Prescriber to Patient





Pharmaceutical Art

















Fagron Sterile Services Wichita, US





Fagron France

Thiais – France



Fagron




FArmaceutische **GRON**dstoffen Founded in 1990

Global leader in personalized medicine

Complying with highest quality standards

Scientific driven product innovations

Disciplined acquisition strategy, creating synergies and cross-selling opportunities



Fagron Growth Development




Fagron DNA, Strategy and Leadership




Fagron Family Rules





Fagron Values

























Fagron Leadership Team



Fagron Innovations



Fagron Technologies





PINEtonina



Phytocomplex that promotes relaxation

Improves quality of sleep

Quick effect

3 No toxicity

2

4

Mechanism of action

Fagron Genomics




1 Use of genetic information to diagnose, prevent and cure

- 2 Identification of genetic variations for more effective personalized treatments
 - 3 Focus on 3 key markets: Personal genomics, clinical genetics and clinical sequencing

Controlled Substances Sterile





MioDesin®





 Fagron developed and introduced MioDesin® and Gestrinone in Pentravan® for the treatment of Endometriosis and Leiomyoma

Research Article Journ	Journal of Clinical Review & Case Reports				
reatment of Endometriosis and Leion nd Gestrinone in Pentravan Through t	nyoma with the Association of Miodesin he Vaginal Route				
lugo Maia ¹¹ , Wilson Saback ² , Charice Haddad ² and P	aulo R Sityu"				
Medical Coordinator, Instituto da Mulher, Italgara Memorial Day Heipital Safrador, Babba, Brazil					
Department of Life Sciences, State University of Bahia (UNER) Salvador, Bahia, Brazil	"Corresponding arthor Dags Muta, Institute da Mallan, Ragara Mismorial Dispital Dia, Contro Madato Lasar Pauling, Jua Altan Informeto de Barona, 197 (2017) 41825-018- Tel: 3207/0355-11 smith Remainderers conciler				
'Instituto da Malher, Inigare Memorial Day Hospital Salvador; Baloa, Brasil	Automitted 10 kep 2018. Accepted 17 kep 2018. Published 24 kep 2018				
'Gynecology and Obstetrics, Universidade Laterana do Brasil Gareen, Rie Grande de Sal, Brazil	and an approximation to approximate				
partners with Resemption and Conductorbanic Algodium ¹⁰⁰⁰ were discovered and algodium ¹⁰⁰⁰ were discovered and algodium ¹⁰⁰⁰ were discovered and algodium ¹⁰⁰⁰ respective algodium ¹⁰⁰⁰ respec	Went, 25A wat, 352 and in group A. B and C respectively and a significant reduction to alaritise reduces rotation data of a granter to group their is group C. The productions rates in the law rotal a mean oblest of TM with on significant differences of a granter order and the second transition stand and there alare an angularization granter as covers (TAU) when such a dather alare an angularization granter as covers of Baro in Groups. 2 And endowed in a granter and the granter is granter as an of covers. 2 And endowed				
Keywardh: Pataswan, Madenia, Ontrinsna, Endamatrinin, Latenyma, Petra Pata Latenyma, Petra Pata Latenyma in utawa whose goverh is scathardarfly inflammetics and homeness with a propositions and entrafact [1]. O continuo- nol homeness with a proposition is an effective treatment backgoin large term backgoing of the state of the state backgoing term backgoing the state proposition of the state backgoing term backgoing the product of the state backgoing the proposition of the state backgoing the state backgoing the backgoing term backgoing the state product of the state backgoing state backgoing term backgoing the state backgoing the state backgoing the state backgoing term backgoing the state backgoing the state backgoing the state backgoing term backgoing the state backgoing term backgoing terms and state backgoing term backgoing terms and state backgoing terms and state backgoing term backgoing terms and state back	tures reasons factor (7b sights par-offismentary tytkins. The Lotaris itomstrus extrast sixt furges in products in SV-Seppe Databased reachasism in infihit? To ²² siphts products in the constant fluctures in differentiary could [4]. Concentral differentiation distribution this mobilities in the transmiss of anoman in filteramethyre/income- tion mobilities of the transmission of anoman in the structure of the instantian entropy of the transmission of the structure of the transmission countering entropy of the transmission of the structure of the transmission of interpretation of the transmission. The instantian of the transmission of interpretation of the transmission. For a structure, To ²²				

more require two meaning wearing pairs arrive and the Uncaria. (IDM) production and introducing their growth [3]. Furthermore, as hards a pred analysis of inflammative order to the protector of a great number of inflammative order in its functions.



The Effect of the Association of Miodesin with Gestrinone on Deep Endometriosis Pain

H 1044 (879 [1]

Objective -Gestrinone is a testosterone derivative with anti estrogenic , anti procesterone and endrozenic properties. The objective of this study must be investigate the effect of low doses of pestrinone together with MiodesinTM in PertrevenTM on date endometrics is pain Mathods -This study was carried out in 40 patients with deep andometriosis and severe pain treated vacinally with postrinone associated with Middesin TH in Pentravan TH . Middesin TH is the brand name of a vegetal extract prepared from the Uncara tormentosa by Facron/Netherland) and standardized to contain 4 % of oxindate alkaloids which are known to be potent inhibitors of NF-Kaopa b activation. Patient Intervention - The patients were divided in two groups . In group A (n=20) they were treated with a low dose of pestrinone in Pentravan¹¹⁴ (Fapron) (2.5 mg)twice a week administered vapinally . In proup B (n=20)pestimone was administered in the same dose, together with Micdesin¹⁹ . Micdesin¹⁹ was used in the vagina daily in a close of 500 mg in 3 mi of Pentravan . Patients in both groups were concomitantly treated onally with 100 mg of Pinus pinaster , 400 mg of Silimarin and 400 mg of Saw palmetto to diminish androgenic side effects and provide hepatic protection .Main Outcome Measure The main outcome investigated was the decrease in total pain scores evaluated by visual analogic scale (VAS) before and after two months of treatment Results Gestrinone in the lower dose of 2,5 mg significantly decreased total pain scores (VAS) in both groups . Before treatment they were 9 but after the second month pain scores decreased significantly to 3 and 0.6 in group A and B respectively. The difference between the groups was statistically significant (p=0.0002). There were also significantly more pain free patients in group B than in Group A (50%versus20%). Side effects were affecting 20% of the patients in both groups and consistent mainly in oly skin . Liver enzymes were not affected and SHBG levels decreased in both groups. Conclusion-These results suggest that vaginal Microssin significantly increased the effectiveness of Gestrinone to treat pelvic pain in patients with deep endometricsis , rendering 80% of them pain free after the second month of treatment .

[1] INSTITUTO DA NULLER, Severa

1 SGI 1 T SCIETY OF GYNECOLOGICA



Fagron US Minneapolis - US






FAGRON

H1-2018 Headlines

Financial

- Turnover increased 5.0% (12.1% CER) to € 230.9m
- REBITDA increased 1.1% (6.9% CER) to € 48.7m
- Recurrent net profit increased 6.6% to € 22.3m
- Operational cash flow of € 34.4m
- Net financial debt/REBITDA ratio of 2.72



Operational Review H1-2018



← 🔁

Florien

Piracicaba – Brazil



Selorien




(x € 1,000)	H1-2018	H1-2017	Total growth	Total growth CER	Organic growth	Organic growth CER
Fagron	227,285	216,551	+5.0%	+12.1%	+1.7%	+8.4%
HL Technology	3,638	3,461	+5.1%	+14.2%	+5.1%	+14.2%
Total	230,923	220,012	+5.0%	+12.1%	+1.7%	+8.5%
CER - constant exchange rates						

CER = constant exchange rates

- Organic turnover growth CER of 8.5%
- Organic turnover growth CER in all regions
- Growth acceleration in North- and South-America in Q2

Turnover Development



Fagron Europe



(x € 1,000)	H1-2018	H1-2017	Δ
Turnover	127,536	127,220	+0.2%
REBITDA	32,667	32,724	-0.2%
REBITDA margin	25.6%	25.7%	

- Organic turnover growth CER of 1.9%
- REBITDA decreases 0.2%; margin decreases 10bps to 25.6%
- Focus on innovative products resulted in strong growth of Brands
- Temporarily reduction of capacity in one of the Dutch compounding facilities to be able to invest in further increasing the quality of the facility and processes



(x € 1,000)	H1-2018	H1-2017	Δ
Turnover	48,880	49,450	-1.2%
REBITDA	9,691	10,054	-3.6%
REBITDA margin	19.8%	20.3%	

- Organic turnover growth CER of 13.3%
- REBITDA decreases 3.6%; margin decreases 50bps to 19.8%
- Strong turnover growth driven by:
 - Growth of underlying markets and growth in number of compounding pharmacies (+8.8% to 7,545)
 - Focus on the development and introduction of innovations and patented concepts
- 25 new innovations introduced during Consulfarma in Brazil
- All Chemistry fully integrated and rebranded to Organic Compounding



(x € 1,000)	H1-2018	H1-2017	Δ
Turnover	50,869	39,880	+27.6%
REBITDA	5,610	5,452	+2.9%
REBITDA margin	11.0%	13.7%	

- Organic turnover growth CER of 22.3%
- REBITDA increases 2.9%; margin decreases 270bps to 11.0%
- REBITDA margin decreased due to the FTE increase at FSS-Wichita
- FCS-sterile performing in-line with expectations
 - Organic growth CER of 27.5% (Q2-18: 34.6%)
 - FSS-Wichita CER: +76.2% (Q2-18: 90.9%)
- Essentials/Brands:
 - Organic growth CER of 7.6%, driven by all activities
 - Good progress on integration of Humco

Pharmaline

Oldenzaal - The Netherlands



Turnover (in € million) **230.9**

- Turnover increases 5.0% or 12.1% at CER
- Organic increase of 1.7% or 8.5% at CER

Gross margin (in € million) **141.9**

- Gross margin increased by € 5.0m (+3.7%)
- Gross margin as percentage of turnover decreased to 61.5% due to the renewal of contracts in H2-17 and the sale of the French pharmacy
- Gross margin increased 70bps compared to H2-17

Operating costs (in € million) -93.3

- Operating costs as a percentage of turnover remained unchanged and amounted to 40.4% in H1-18
- Operating costs increased by 5.1%, mainly due to the acquisition and integration of Humco and the increase of FTE at FSS in Wichita

REBITDA (in € million) **48.7**

- REBITDA increased by 1.1% (+6.9% CER) to € 48.7m
- REBITDA as percentage of turnover decreased by 80bps to 21.1%

Non-recurring (in € million) -4.7 Non-recurring result amounts to -€ 4.7m and consists of the settlement with the former owners of JCB Laboratories (US), dismissal costs and acquisition costs

EBITDA (in € million) **44.0** • EBITDA decreased by 6.8% to € 44.0m due to the increase in non-recurring elements (mainly JCB settlement)

•

DA (in € million) **-9.5** • DA amounted to € 9.5m, an increase of 8.6% compared to H1-17, partly due to amortization of the Humco brand

EBIT (in € million) **34.5** EBIT decreased by 10.3% to € 34.5m

Fin. result (in € million) **-10.5**

- Financial result decreased by 21.2% to € 10.5m
- The decrease was mainly due to the repayment of the bond in July 2017, offset by FX-results and higher debt due to the Humco acquisition

Taxes (in € million) **-5.2**


- Effective tax rate amounted to 21.8% compared to 18.6% in H1-17
- Effective cash tax rate amounted to 15.1%

Net profit (in € million) **18.8**

- Net profit amounted to € 18.8m, a decrease of 10.8% compared to H1-17
- Recurrent net profit increased by 6.6% to € 22.3m

Net Financial Debt consolidated





Summary

- Turnover growth driven by all areas -Acceleration in Q2
- Good progress with integration Humco
- Investing in people, systems and product development to further accelerate growth
- Focus remains on:
 - Continued strong organic growth
 - Targeted acquisitions in our core markets
- Positive about the future and confident that the positive trend will continue in 2018



Q3-2018 Trading Update

Fagron Hellas Trikala - Greece




Fagron


Headlines Q3-2018

Highlights

- Turnover increased by 11.8% to € 114.9m
- Organic growth CER of 10.1%
- Growth driven by all regions
- Solid growth of Brands




Turnover Development



Fagron Europe

(x € 1,000)	Q3-2018	Q3-2017	Total growth	Total growth CER	Organic growth	Organic growth CER
Turnover	57,316	56,664	+1.2%	+1.4%	+1.2%	+1.4%

- Organic growth CER of 1.4%
- Strategic focus on Brands resulted in strong growth
- Temporarily reduction of capacity in one of the Dutch compounding facilities to be able to invest in further increasing the quality of the facility and processes. Negative impact of € 1.5m in Q3-2018








(x € 1,000)	Q3-2018	Q3-2017	Total growth	Total growth CER	Organic growth	Organic growth CER
Turnover	25,467	25,753	-1.1%	+21.9%	-5.2%	+16.9%


- Organic growth CER of 16.9%
- Strong growth of Essentials and Brands in Brazil
 - Essentials: High product availability
 - Brands: Continued launch of new and innovative products
- Strong growth at FCS in Colombia





(x € 1,000)	Q3-2018	Q3-2017	Total growth	Total growth CER	Organic growth	Organic growth CER
Turnover	30,392	18,543	+63.9%	+63.5%	+29.9%	+28.8%

- Organic growth CER of 28.8%
- FCS-sterile performing in-line with expectations
 - Organic growth CER of 33.5%
 - Organic growth CER FSS-Wichita: +84.2%
- Essentials/Brands:
 - Organic growth CER of 14.2%, driven by Brands and Essentials
 - Good progress with integration of Humco



Summary

- Strong turnover growth driven by all areas
- Good progress with integration Humco
- Focus remains on:
 - Further expansion of leading market positions in key regions
 - Innovation-driven organic growth
 - Strategic acquisitions
- Confident about Q4-2018
- Excellently positioned for further growth in 2019



Shareholder Structure

FSBA

Hoogeveen - The Netherlands



Fagren

Shareholder Structure



	Number of shares	% of voting rights
Waterland Private Equity Fund VI CV, Balcaen, Fagron	22,656,725	31.54%
Alychlo NV / Marc Coucke	10,749,267	14.96%
JPMorgan Asset Management Holdings Inc.	3,496,585	4.87%
Evermore Global Advisors, LCC	2,203,472	3.07%
Carmignac Gestion	1,492,006	4.65%

- Article 11 of the articles of association of the company specifies that participations must be notified as soon as a threshold of 3%, 5% and any multiple of 5% has been passed
- The number of Fagron shares with voting rights is 71,843,904. The total number of voting rights (denominator) is 71,843,904
- The notification of Carmignac Gestion was received on March 18, 2016 and is based on a denominator of 32,111,827







Important information about forward-looking statements

Certain statements in this presentation may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason.